Premium
Pharmacokinetics of Cefodizime in Volunteers with Normal or Impaired Renal Function
Author(s) -
Conte John E.
Publication year - 1994
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1994.tb01982.x
Subject(s) - hemodialysis , pharmacokinetics , renal function , medicine , impaired renal function , creatine , urology , creatinine , elimination rate constant , gastroenterology , volume of distribution
The pharmacokinetics of single, 1‐ or 2‐g intravenous doses of cefodizime were studied in subjects with normal, impaired renal function or requiring chronic hemodialysis. Drug concentrations were measured using high‐performance liquid chromatography. Forty‐five subjects (20 with creatinine clearance of ≥90 mL/min, 15 with creatine clearances between 5 and 89 mL/min, and 10 requiring chronic hemodialysis) were studied. The concentration—time curve of cefodizime was best represented by an open two‐compartment model. The elimination half‐lives in subjects with normal (Group 1) and impaired renal function (Group 2) or requiring chronic hemodialysis (Group 3) were 4.14 ± 1.55, 5.10 ± 2.24, and 10.1 ± 6.01 hours, respectively (Group 3 versus 1 or 2 , P < .05; Group 1 versus 2 , P > .05). The total body (serum) clearances in the same groups were 3 ± 0.52, 2.22 ± 0.61, and 0.99 ± 0.33 L/hour, respectively (Group 1 versus 2 or 3 , P < .05; Group 2 versus 3 , P < .05). Although renal function has an effect on the pharmacokinetics of cefodizime, its effect on the elimination half life is marginal in subjects with creatinine clearance of more than 25 mL/min. In individuals with more severe renal impairment or those requiring chronic hemodialysis, dosage adjustment would be required .